LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.  

LENZ Therapeutics

Sr. Regulatory Operations Specialist

Director, Trade - Pharmaceutical Industry

Specialty Sales Representative, Eye Care - Long Beach, CA

Specialty Sales Representative, Eye Care - Louisville, KY

Specialty Sales Representative, Eye Care - Birmingham, AL

Specialty Sales Representative, Eye Care - Cincinnati, OH

Specialty Sales Representative, Eye Care - Oklahoma City, OK

Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan

LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq

Chris Lievens, OD MS PhD, is motivated by an innovative presbyopia treatment that ensures better results for him and his patients. 
 
"As both a practitioner and a presbyope, I'm anticipating the transformative impact a new solution could have on my own life and the lives of my patients."
 
www.EyeAmSelective.com
#presbyopia 

 LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia 

 Lenz Therapeutics' Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape - TipRanks.com 

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study - ETHealthWorld

A gene editing biotech’s struggles end with reverse merger - BioPharma Dive

 LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 

 LENZ Therapeutics, Inc. (LENZ) Files $500M Mixed Shelf 

Lenz presbyopia drop meets endpoints in near vision improvement in phase 3 trials - Healio

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

View All News

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

LENZ Therapeutics welcomes Apple Decena as our new Senior Accountant. Apple brings a strong background in accounting and has over 8 years of experience in Accounts Receivable and Accounts Payable roles. 

Join us in welcoming Apple to the team!

Behind the Bell: LENZ Therapeutics - Nasdaq

 Lenz Therapeutics management to meet with Piper Sandler 

 A gene editing biotech's struggles end with reverse merger 

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia - Stock Titan

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials - Business Wire

Graphite Erased: LENZ to Merge with Gene Editing Therapy Developer - Genetic Engineering & Biotechnology News

Lenz Therapeutics inks $125M licensing deal with Lotus - Axios

 LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference 

LENZ Therapeutics gets fresh set of eyes with $47M funding to bring eyedrop to market - Fierce Biotech

Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

View Press Release

LENZ Therapeutics welcomes Mina Ghazizadeh as a Human Resources Generalist. 

Mina attended the University of San Diego, where she played on the women’s soccer team, before earning her graduate degree in Industrial/Organizational Psychology. Most recently, she worked as the People & Culture Specialist with the Portland Trail Blazers. 

Join us in welcoming Mina to the team!

rss_feedRSS News Feed

Mark Schaeffer, OD, FAAO believes presbyopia solutions are active and continuously changing. 
 
"The presbyopia market is dynamic. It reflects our patients’ evolving visual needs and their desire for a solution that provides clear vision on their own terms. Vision is dynamic, too—so shouldn’t we consider a solution that mirrors that?"
 
 www.EyeAmSelective.com
 #presbyopia

 Lenz Therapeutics Completes Merger With Graphite Bio, Inc. 

 LENZ Therapeutics reports positive Phase 3 results for LNZ100 By Investing.com 

LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

 Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c) 

Lenz Therapeutics: Upcoming PDUFA, Strong Data, Some Risks (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times

 LENZ Therapeutics Merges With Graphite Bio 

LENZ Therapeutics submits NDA for drops to treat presbyopia - Healio

LENZ Therapeutics' LNZ100 Hits FDA Milestone, Reports 74% Success in Phase 3 Trial - StockTitan

 Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study 

LENZ Therapeutics gets fresh set of eyes with $47M ...

 Geopolitics, rates drag on private equity deals; Israel's high PE ... 

A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results - Genetic Engineering & Biotechnology News

 Lenz Therapeutics' eye drop helps improve vision in late-stage study 

 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights 

Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com

LENZ Therapeutics and Lotus Pharmaceutical Co., Ltd Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia.

LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia, including Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore.

Read the full press release here: https://lnkd.in/e5QvyN6v

See results

 LENZ Therapeutics, Inc. (LENZ) Files for 13.07M Share Offering by Selling Stockholders 

 Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics 

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St

LENZ Grants Lotus Licensing Rights to Presbyopia Treatment in South Korea, Southeast Asia - marketscreener.com

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress - Business Wire

Join LENZ Therapeutics at American Society of Cataract and Refractive Surgery (ASCRS) this week.

Stop by booth #1359 to learn more about the future of presbyopia solutions.

 LENZ Therapeutics’ $30 Million Private Placement Financing 

Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

LENZ - LENZ THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan

LENZ Therapeutics: Freedom From Reading Glasses (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

LENZ Therapeutics Finds $83.5M In Series B - socalTech.com

 Graphite Bio to Pay Special Dividend Linked to Lenz Therapeutics Merger 

LENZ Therapeutics Merges With Graphite Bio - San Diego Business Journal

 Lenz Therapeutics, Corxel Pharmaceuticals report topline data from JX07001 trial 

We are hiring! LENZ Therapeutics is searching for a Sr. Regulatory Operations Specialist. 

This position will be responsible for formatting and publishing regulatory submissions, supporting the implementation and maintenance of our Regulatory Information Management and publishing systems, and ensuring compliance with regulatory submissions requirements throughout the product lifecycle. 

Read the full description and click the link to apply: https://lnkd.in/gWSAjYU3 

 LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 

 LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights 

 [Video] LENZ Therapeutics on LinkedIn: LENZ Therapeutics welcomes David Choromanski as Vice President of… | 52 ... 

 LENZ Therapeutics Stock Gains 16% After Positive Vision-Loss Trial Data 

LENZ Therapeutics, Inc.

Investors & Media

We are hiring! LENZ Therapeutics is searching for a Sr. Quality Specialist.

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products.

Other responsibilities for this role include date review and verification, support administration of electronic QMS and Regulatory software(s), product complaint handling and management review program. 

If you are ready to join our team, click link below to apply: https://lnkd.in/gmEr7VXj

Lenz Therapeutics price target raised to $47 from $44 at Citi - TipRanks

 TD Cowen Upgrades LENZ Therapeutics Inc (LENZ) to Buy 

LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq

 LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 

Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN

LENZ Therapeutics welcomes Mansi Parikh, OD as a Medical Science Liaison in the Mid-South. 

Mansi earned her Doctor of Optometry from the New England College of Optometry and spent six years owning and operating multiple subleased clinics across the greater Atlanta area. Her interest in innovation led her to contribute to human factors research, where she applied clinical insights to improve the safety and usability of wearable devices. Most recently, she served as a Clinical Research Optometrist where she served as an investigator for contact lens clinical trials. 

 
Join us in welcoming Mansi to the team!

A phenomenal day for LENZ Therapeutics in New York, where we hosted a standout Commercial Day at Nasdaq, showcasing the commercial readiness of LNZ100, our potential best-in-class solution in development for presbyopia.

The event featured powerful first-hand insights from both patients and eye care professionals who participated in our Phase 3 clinical trial — bringing real-world impact to life.

We also shared an exciting preview of our commercial strategy and were thrilled to sit down with special guest Tiffani Thiessen, who brought her own voice to the conversation around presbyopia awareness.

We are energized by the overwhelmingly positive feedback. Thank you to everyone who joined us and to the broader LENZ community for your continued support.

#NASDAQ #Presbyopia #EyeCare #TiffaniThiessen

 Lenz Therapeutics' Eye Drop Helps Improve Vision in Late-Stage Study 

Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics - Business Wire

Lenz Therapeutics Raises $47M in Series A Financing - FinSMEs

Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio - Wilson Sonsini

San Diego’s Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses - San Diego Union-Tribune

Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - Stock Titan

Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100 - TipRanks

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1% - What's Next? - MarketBeat

LENZ Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials - Business Wire

Mitch Ibach, OD FAAO is curious about discovering the potential advancements in presbyopia solutions. 
 
"I'm curious to see how presbyopes adopt a new solution and the near-vision improvement they can achieve. Finding the right treatment for each patient is crucial. Curiosity drives me to seek better options for clearer vision, and I'm eager to explore how future solutions can complement existing treatments."
 
www.EyeAmSelective.com
#presbyopia 

LENZ Therapeutics welcomes Kashif Qadeer, O.D. as a Medical Science Liaison in Southern California.

Kashif earned his Doctor of Optometry degree from the Southern California College of Optometry in 2007, following early research experience in ocular medications. He completed a residency in Ocular Disease at the VA Eye Clinic in Las Vegas, then worked in a large ophthalmology practice focusing on LASIK co-management, contact lenses, and clinical research. He later ran a successful two-location private practice in Orange County for over 13 years. Most recently, he returned to the industry side, contributing to clinical research with a major pharmaceutical company.

Join us in welcoming Kashif to the team!


                Earnings Release
                HTML
            

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

 LENZ Therapeutics to Host Commercial Day on April 15, 2025 

GRAPHITE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia - Business Wire

LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq

LENZ Therapeutics announces positive results from Phase 3 CLARITY trials - Optometry Times

LENZ Therapeutics welcomes Joseph B. as Regional Sales Director, East Coast. Joseph comes to LENZ with over 10 years of experience rebuilding and leading high performing teams in multiple specialties. Joseph has extensive experience in eye care from his time at Aerie and Alcon. Joseph also brings a diverse business background to LENZ, including CPG sales, Trade Marketing, Retail Sales Management, and multiple Leadership Certifications. His vast experience in Sales Leadership has helped Joe develop an award winning and successful track record over his career including several President Club Awards. These skills will make Joe a key player as we drive towards commercial readiness.

Join us in welcoming Joe to the team!

LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3% - Should You Buy? - MarketBeat

Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz - Fierce Biotech

LENZ Therapeutics

Business:

About: